Durham-based Metabolon has inked a deal to commercialize its Quantose IR insulin resistance test in 30 international markets with European-based network Synlab. It will be introduced in Spain first. Other termss of the deal were not disclosed.
“This collaboration between our two companies is an important step toward making Quantose IR and future precision medicine and diagnostics products widely available across the globe,” Metabolon CEO John Ryals said in a statement.
Its previous agreement with Metia Biotech to commercialize the test as well as another one in 14 European countries including Spain expired in early 2015.